Geraniin

Geraniin is a TNF-α releasing inhibitor with numerous activities including anticancer, anti-inflammatory, and anti-hyperglycemic activities, with an IC50 of 43 μM.

Product information

CAS Number: 60976-49-0

Molecular Weight: 952.64

Formula: C41H28O27

Chemical Name: (7S, 8R, 26S, 28S, 29S)-1, 13, 14, 15, 18, 19, 20, 34, 35, 39, 39-undecahydroxy-2, 5, 10, 23, 31-pentaoxo-6, 9, 24, 27, 30, 40-hexaoxaoctacyclo[34.3.1.0, .0, .0, .0, .0, .0, ]tetraconta-3, 11, 13, 15, 17, 19, 21, 32(37), 33, 35-decaen-28-yl 3, 4, 5-trihydroxybenzoate

Smiles: OC1(O)C2C3=C4OC1(O)C(=O)C=C2C(=O)O[C@H]1[C@@H]2COC(=O)C5=CC(O)=C(O)C(O)=C5C5=C(C=C(O)C(O)=C5O)C(=O)O[C@H]1[C@H](OC(=O)C3=CC(O)=C4O)[C@@H](O2)OC(=O)C1C=C(O)C(O)=C(O)C=1

InChiKey: JQQBXPCJFAKSPG-AZSQBUALSA-N

InChi: InChI=1S/C41H28O27/c42-13-1-8(2-14(43)24(13)48)34(54)67-39-33-32-30(64-38(58)12-6-19(47)41(61)40(59,60)23(12)22-11(37(57)66-33)5-17(46)27(51)31(22)68-41)18(63-39)7-62-35(55)9-3-15(44)25(49)28(52)20(9)21-10(36(56)65-32)4-16(45)26(50)29(21)53/h1-6,18,23,30,32-33,39,42-46,48-53,59-61H,7H2/t18-,23?,30-,32+,33-,39-,41?/m0/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 100 mg/mL (104.97 mM; Need ultrasonic)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

The IC50 value of TNF-α release inhibition is 43 μM for Geraniin. Geraniin has long been used as a medicinal herb and possesses numerous activities including anticancer, anti-inflammatory, and anti-hyperglycemic activities. Geraniin significantly decreases the viability of OVCAR3 and SKOV3 cells in a concentration-dependent fashion. The IC50 value for Geraniin treatment is 34.5±2.8 μM in OVCAR3 cells and 23.6±1.9 μM in SKOV3 cells. However, Geraniin up to the maximal concentration used (80 μM) has no significant impact on the viability of normal human ovarian surface epithelial cells. Treatment with 10 and 40 μM of Geraniin for 48 h causes a significant increase in apoptosis (16.8±1.2% and 22.6±1.4%, respectively), compared with control OVCAR3 cells (3.9±1.1%). Similar results are observed in SKOV3 cells.

In Vivo:

Treatment with Geraniin prior to application of okadaic acid delays development of tumors compared with control group, reduces the percentage of tumor bearing mice from 80.0% to 40.0%, and reduces the average numbers of tumor per mouse from 3.8 to 1.1 in week 20. It is also showed that oral administration of Geraniin to rats (50 mg/kg/d or 100 mg/kg/d) inhibit the elevation of serum total cholesterol, lipid peroxide, free fatty acid, triglyceride, glutamic oxaloacetic transaminase and glutamic pyruvic transaminase induced by treatment with peroxidized oil.

References:

1. Okabe S, et al. New TNF-alpha releasing inhibitors, geraniin and corilagin, in leaves of Acer nikoense, Megusurino-ki. Biol Pharm Bull. 2001 Oct;24(10):1145-8.
2. Wang X, et al. Geraniin suppresses ovarian cancer growth through inhibition of NF-κB activation and downregulation of Mcl-1 expression. J Biochem Mol Toxicol. 2017 Sep;31(9).

Products are for research use only. Not for human use.